Sanofi-Aventis has room for sales force reductions: Spek

Share this article:

Sanofi-Aventis has the flexibility to further reduce its sales force, the drugmaker's head of pharmaceuticals Hanspeter Spek said during a post-results conference call on Wednesday.

“I don't believe our overall sales force will increase – there will be inside restructuring,” Spek told Reuters.

Spek said around 10% of the US sales force typically leaves each year and another 10% are external hires.

Sanofi has already cut its US sales force by 11% since 2005.

Meanwhile, Sanofi reported that second quarter sales of its sleeping pill Ambien fell 42%. The Paris-based drugmaker was counting on weight-loss drug Acomplia to boost company growth but had to withdraw the drug last month after an FDA expert panel linked it to suicide and depression.

“They're not in good shape,” Eric le Berrigaud, an analyst at Raymond James in Paris, told Reuters. “Their portfolio is pretty old now, they really need new products.”

Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.